HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Marder, K. Articles by Mayeux, R. Search for Related Content PubMed PubMed Citation Articles by Marder, K. Articles by Mayeux, R.

The apolipoprotein 4 allele in Parkinson's disease with and without dementia

Gertrude H. Sergievsky Center (Drs. Marder, Cote, Tang, and Mayeux), the Departments of Neurology (Drs. Marder, Cote, Tang, and Mayeux, and H. Mejia and B. Alfaro), Psychiatry (Dr. Mayeux), and Pathology (Drs. Maestre, Tycko, and Mayeux), College of Physicians and Surgeons at Columbia University, New York the Center for Alzheimer's Disease Research (Drs. Marder, Maestre, Tycko, and Mayeux), New York and the Division of Epidemiology, Columbia University School of Public Health (Dr. Mayeux and A. Halim), New York, NY.

The 4 isoform of apolipoprotein E (Apo-E) may confer genetic susceptibility for familial and sporadic Alzheimer's disease (AD). Because dementia in AD and Parkinson's disease (PD) share many biologic and clinical features, we determined the Apo-E genotypes for 79 patients with PD, 22 of whom were demented, and for 44 age-matched healthy elderly controls from the same community. We hypothesized that if the dementia was similar to AD, there would be a higher allele frequency of apolipoprotein 4 (Apo4) in demented PD patients compared with nondemented PD patients and controls. The 4 allele frequency for PD without dementia was 0.132, for PD with dementia, 0.068, and for controls, 0.102. There was no association between Apo4 and dementia in the PD patients. We conclude that the biologic basis for dementia in PD may differ from that of AD.

Address Correspondence and reprint requests to Dr. K. Marder, G.H. Sergievsky Center, 630 West 168th Street, Columbia University; New York, NY 10032.

Support for this project came from the following federal grants: AG10963, AG07232, AG08702, and RR00645, and from the Parkinson's Disease Foundation and the Charles S. Robertson Memorial Gift for Alzheimer's Disease Research from the Banbury Fund.

Received November 22, 1993. Accepted in final form January 20, 1994.

This article has been cited by other articles:

				X. Huang, P. Chen, D. I. Kaufer, A. I. Troster, and C. Poole Apolipoprotein E and Dementia in Parkinson Disease: A Meta-analysis Arch Neurol, February 1, 2006; 63(2): 189 - 193. [Abstract] [Full Text] [PDF]

				X. Huang, P. C. Chen, and C. Poole APOE-{epsilon}2 allele associated with higher prevalence of sporadic Parkinson disease Neurology, June 22, 2004; 62(12): 2198 - 2202. [Abstract] [Full Text] [PDF]

				B. S. Harhangi, M. C. de Rijk, C. M. van Duijn, C. Van Broeckhoven, A. Hofman, and M. M. B. Breteler APOE and the risk of PD with or without dementia in a population-based study Neurology, March 28, 2000; 54(6): 1272 - 1276. [Abstract] [Full Text] [PDF]

				K. Marder, M.-X. Tang, B. Alfaro, H. Mejia, L. Cote, E. Louis, Y. Stern, and R. Mayeux Risk of Alzheimer's disease in relatives of Parkinson's disease patients with and without dementia Neurology, March 1, 1999; 52(4): 719 - 719. [Abstract] [Full Text]

				The French Parkinson's Disease Genetics Study Grou Apolipoprotein E genotype in familial Parkinson's disease J. Neurol. Neurosurg. Psychiatry, September 1, 1997; 63(3): 394 - 395. [Abstract] [Full Text] [PDF]

				Y. Ben-Shlomo, A. S. Whitehead, and G. D. Smith Parkinson's, Alzheimer's, and motor neurone disease BMJ, March 23, 1996; 312(7033): 724 - 724. [Full Text]